

Supplementary Table e-1. Baseline characteristics of non included and included relapsing-remitting multiple sclerosis patients. **A)** for the whole cohort of patients, **B)** for fingolimod-treated patients, and **C)** for natalizumab-treated patients.

A) Whole cohort of patients	Included (n=629)	Non included (n=184)	p value
Female –n-%	479 (76.2)	129 (70.1)	0.1015
Age at the treatment initiation, years-mean(SD)	37.0 (9.6)	38.6 (9.7)	0.0413
Disease duration at treatment initiation, years-mean (SD)	8.5 (6.4)	9.9 (6.9)	0.0138
EDSS score-mean (SD)	2.6 (1.3)	2.6 (1.4)	0.9939
EDSS score of 3 to 5.5- n (%)	288 (45.8)	77 (41.9)	0.3552
Patient with previous treatment ^a -n (%)	556 (88.4)	164 (89.1)	0.8953
Patients with relapse in the preceding year-n (%)			
≥1 relapse	526 (83.6)	122 (66.3)	<0.0001
≥2 relapses	264 (42.0)	52 (28.3)	0.0008

B) fingolimod-treated patients	Included (n=303)	Non included (n=100)	p value
Female- n (%)	225 (74.3)	73 (73)	0.7941
Age at the treatment initiation, years-mean(SD)	37.2 (9.2)	41.2 (9.3)	0.0002
Disease duration at treatment initiation, years-mean (SD)	9.0 (6.8)	11.3 (7.0)	0.0060
EDSS score-mean (SD)	2.4 (1.3)	2.4(1.2)	0.7861
EDSS score of 3 to 5.5- n (%)	122 (40.3)	34 (34)	0.2880
Patients with previous treatment ^a -n (%)	263 (86.8)	92 (92)	0.2124
Patients with relapse in the preceding year-n (%)			
≥1 relapse	233 (76.9)	57(57)	0.0002
≥2 relapses	92 (30.4)	21 (21)	0.0737

C) natalizumab-treated patients	Included (n=326)	Non included (n=84)	p value
Female-n (%)	254 (77.9)	56 (66.7)	0.0453
Age at the treatment initiation, years-mean(SD)	36.8 (9.9)	35.6 (9.4)	0.0474
Disease duration at treatment initiation, years-mean (SD)	8.0 (6.1)	8.4 (6.6)	0.3956

EDSS score-mean (SD)	2.8 (1.3)	2.9(1.5)	0.1055
EDSS score of 3 to 5.5- n (%)	166 (50.9)	43 (51.2)	1.0000
Patients with previous treatment ^a -n (%)	293 (89.9)	72 (85.7)	0.3264
Patients with relapse in the preceding year-n (%)			
≥1 relapse	293 (89.9)	65 (77.4)	0.0050
≥2 relapses	172 (52.8)	31 (36.9)	0.0103
